Andrew Stamford
Private Equity Investor at Deerfield Management Co. LP (Private Equity)
Profile
Andrew (Andy) Stamford, Ph.D., is a Vice President, Chemistry, Deerfield Discovery and Development, and joined the Firm in 2020.
Prior to Deerfield, Dr. Stamford spent over three years at Bridge Medicines as Vice President, Chemistry, and then as Senior Vice President of Research and Development.
During this time, he also served as Vice President, Chemistry at the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).
Dr. Stamford has over 25 years of combined experience at Merck and Schering-Plough Research Institute working in small molecule drug discovery from hit-to-lead to clinical candidate.
He is the co-author of more than 70 peer-reviewed publications and an inventor on over 100 issued US patents.
Dr. Stamford holds a B.Sc.
in Organic Chemistry from University of Tasmania and a Ph.D.
in Organic Chemistry from University of Sydney
Andrew Stamford active positions
| Companies | Position | Start |
|---|---|---|
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Private Equity Investor | 2020-04-30 |
Former positions of Andrew Stamford
| Companies | Position | End |
|---|---|---|
Bridge Medicines LLC
 Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Private Equity Investor | 2020-04-30 |
Tri-Institutional Therapeutics Discovery Institute, Inc.
 Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Private Equity Investor | 2018-07-31 |
Training of Andrew Stamford
| University of Tasmania | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Finance |
Bridge Medicines LLC
Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Health Technology |
Tri-Institutional Therapeutics Discovery Institute, Inc.
Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Commercial Services |
- Stock Market
- Insiders
- Andrew Stamford
